Logo

APUS

Apimeds Pharmaceuticals US, Inc

APUS

Apimeds Pharmaceuticals US, Inc • NYSE
$2.90 ▲ 32.42% (+0.71)
Market Cap $36.44 M
52w High $4.03
52w Low $1.37
Dividend Yield 0%
P/E -7.07
Volume 386.89K
Outstanding Shares 12.57M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $1.843M ▼ $-1.781M ▲ 0% $-0.14 ▲ $-1.773M ▲
Q2-2025 $0 $2.664M ▲ $-2.662M ▼ 0% $-0.26 ▼ $-2.639M ▼
Q1-2025 $0 $364.368K ▲ $-402.397K ▼ 0% $-0.035 ▼ $-364.365K ▼
Q4-2024 $0 $275.613K ▼ $-311.633K ▲ 0% $-0.027 ▲ $-275.583K ▲
Q3-2024 $0 $299.999K $-332.521K 0% $-0.029 $-299.883K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $6.987M ▼ $9.25M ▼ $1.089M ▲ $8.161M ▼
Q2-2025 $8.735M ▲ $10.547M ▲ $809K ▼ $9.738M ▲
Q1-2025 $250.342K ▲ $259.904K ▲ $2.02M ▲ $-1.761M ▼
Q4-2024 $3.455K ▼ $13.057K ▼ $1.371M ▲ $-1.358M ▼
Q3-2024 $26.571K $36.907K $1.083M $-1.046M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.781M ▲ $-1.726M ▲ $-22.54K ▼ $0 ▼ $-1.749M ▼ $-1.749M ▲
Q2-2025 $-2.662M ▼ $-3.361M ▼ $-13.369K ▼ $11.859M ▲ $8.485M ▲ $-3.374M ▼
Q1-2025 $-402.397K ▼ $-20.313K ▲ $0 $267.2K ▲ $246.887K ▲ $-20.313K ▲
Q4-2024 $-311.633K ▲ $-99.616K ▲ $0 $76.5K ▼ $-23.116K ▲ $-99.616K ▲
Q3-2024 $-332.521K $-186.755K $0 $150K $-36.755K $-186.755K

Five-Year Company Overview

Income Statement

Income Statement Apimeds is still a pure development-stage company: it has no product revenue yet and runs consistent losses driven mainly by research and development and general overhead. Earnings per share have been negative for several years, and the loss has been gradually widening as the company prepares for later-stage trials. In practical terms, the income statement tells a simple story: spending to build value in Apitox and the pipeline today, with no commercial offset yet, and high dependence on successful clinical and regulatory outcomes in the future.

Balance Sheet

Balance Sheet Historical line items are not very informative, but the narrative shows a small-company balance sheet dominated by cash from the recent IPO and very limited operating assets. There is no clear indication of meaningful debt, which is a positive from a financial risk standpoint, but it also means equity holders are carrying the funding burden. Most of the company’s real “assets” are intangible — its Apitox program, clinical data, and know‑how — which do not appear clearly on the balance sheet but are central to its value. The balance sheet is therefore light and flexible, yet also exposed to dilution risk if more capital must be raised before any approval or revenue.

Cash Flow

Cash Flow Cash flow is typical for an early biopharma: money flows out steadily to fund trials, staff, and overhead, with nothing coming in from product sales. Operating cash burn has increased as the company ramps late‑stage studies, and capital expenditures appear modest, so most cash outlay is directly tied to R&D and operations rather than heavy equipment. The IPO has provided a temporary cushion, but the company’s future cash position will depend on how quickly it spends on the Phase III program and whether it can secure additional funding or partnerships before its current resources are depleted.

Competitive Edge

Competitive Edge Apimeds has a distinctive niche: a bee‑venom–derived, non‑opioid pain therapy with late‑stage development for knee osteoarthritis and a history of use in another country. This gives it some first‑in‑class potential and a differentiated story versus typical pain drugs. Access to prior clinical and safety data from its Korean partner adds credibility and may shorten the learning curve compared with entirely new concepts. However, patent protection around the core substance is weak, with reliance on trade secrets and process know‑how, which may limit how strong its long‑term moat can be against well‑resourced competitors. The company also operates in a crowded pain and inflammation market, where large pharma players with deeper pockets could respond quickly to any commercial success. Overall, its edge is uniqueness and head start in a narrow area, offset by modest scale and mixed intellectual-property strength.

Innovation and R&D

Innovation and R&D Innovation is where Apimeds is strongest. Apitox leverages a natural, historically used substance and repackages it into a standardized, pharmaceutical‑grade product with a novel route of administration, aiming to offer pain relief without opioids. The company is also exploring broader uses, such as symptom management in multiple sclerosis, which, if supported by data, could significantly expand its potential reach. Beyond Apitox, the “Actual Intelligence” philosophy and the ai² Futures Lab use human expertise and academic partnerships to scout overlooked or shelved drug candidates, a creative and relatively low‑cost way to build a pipeline. The flip side is that all of this remains high‑risk: clinical trials can fail, regulators can disagree, and repurposed or distressed assets often carry hidden scientific or commercial challenges. Still, from an innovation standpoint, Apimeds is clearly trying to punch above its size.

Summary

Apimeds is an early‑stage, single‑product‑centric biopharma story: no revenue yet, ongoing losses, and a balance sheet currently supported by recent IPO cash but likely needing more funding over time. Its investment case revolves almost entirely around the success or failure of Apitox in late‑stage trials for knee osteoarthritis, with additional upside possibilities in multiple sclerosis and future in‑licensed assets. The company’s competitive appeal lies in its non‑opioid, nature‑derived approach, access to prior human data, and a creative, partnership‑driven R&D model. Key risks include clinical and regulatory uncertainty, modest and largely intangible asset backing, limited patent strength, and dependence on capital markets. Overall, this is a high‑uncertainty, innovation‑heavy profile where future clinical outcomes will largely determine whether today’s spending and dilution eventually translate into a sustainable business.

NEWS

November 10, 2025 · 10:00 AM UTC

Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation

Read more

October 14, 2025 · 3:02 AM UTC

Apimeds Pharmaceuticals says “I love my Ducks” with new ai² Futures Lab™ Program collaboration with the University of Oregon's Lundquist College of Business

Read more

September 15, 2025 · 6:24 PM UTC

Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development

Read more

September 11, 2025 · 9:54 PM UTC

Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program

Read more